Dr. Matthew Drake, MDPhD

Matthew T. Drake, MD, Ph.D, is a board certified Endocrinologist at HSS and Chief of the Endocrinology and Metabolic Bone Disease Services where he provides care to patients with metabolic bone diseases, rare bone diseases, and cancers that affect the skeleton. He formerly served as Consultant and Associate Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, including as Chair of the Mayo Clinic Endocrinology Metabolic Bone Disease Group during the decade prior to his move to HSS in January 2025. After receiving his AB degree from Harvard College, where he graduated magna cum laude, Dr. Drake completed his MD and PhD degrees in the Medical Scientist Training Program at Washington University in St. Louis. His clinical training in Internal Medicine was performed at Duke University Medical Center in Durham, North Carolina. He completed his Endocrinology fellowship training at Mayo Clinic in the Clinician-Investigator Pathway, joining the Mayo Clinic staff in 2007. Dr. Drake …has performed basic, translational, and clinical research under NIH-sponsored grants and has published over 130 articles in a variety of scientific journals including the Journal of Bone and Mineral Research, Bone, Nature Medicine, Lancet Diabetes and Endocrinology, JAMA, the Journal of Clinical Investigation, the Journal of Clinical Endocrinology and Metabolism, Osteoporosis International, Lancet Oncology, and Blood. His research focuses on understanding the mechanisms underlying age-associated bone loss and the skeletal microarchitectural changes that accompany this condition, as well as the basis by which monoclonal gammopathies (monoclonal gammopathy of undetermined significance/MGUS and multiple myeloma) induce bone loss and fractures. Dr. Drake has received numerous awards, including the American Society for Bone and Mineral Research (ASBMR) Young Investigator Award and the Mayo Clinic Department of Medicine New Investigator Award. He has previously served, or is currently serving on, the editorial boards of the Journal of Bone and Mineral Research (JBMR), JBMR Plus, the Journal of Clinical Endocrinology and Metabolism, and Mayo Clinic Proceedings. He currently serves as a member of the Scientific Advisory Boards for the Soft Bones Foundation, the Fibrous Dysplasia Foundation, and the Rare Bone Disease Network, and previously served on the Orthopedic Research Society (ORS) and Advances in Mineral Metabolism (AIMM) meeting development committees. He also serves a member of the American Board of Internal Medicine Endocrinology Examination Committee. Dr. Drake has previously served as Chair of the American Society for Bone and Mineral Research (ASBMR) Professional Practice Committee and as a member of the ASBMR Ethics Committee and is a current member of the ASBMR Council. He previously served on the Endocrine Society Annual Meeting Steering Committee. He previously served as a member of the United States Food and Drug Administration (FDA) Bone, Reproductive, and Urologic Drugs Advisory Committee, is a current member of the FDA Endocrine and Metabolic Drugs Advisory Committee, and has served on numerous NIH, US government, foundation, and international grant review committees. At Mayo Clinic, Dr. Drake also served on the Institutional Review Board (IRB) overseeing human studies research, including as IRB Chair for the six years preceding his arrival at HSS.